Global X Guru Index ETF
Latest Global X Guru Index ETF News and Updates
Valeant’s Dermatology Business Felt Pricing Pressure in 2016
Dermatology pricing trends Valeant Pharmaceuticals’ (VRX) dermatology business witnessed intense pricing pressure in 2016, due to a change in the company’s distribution model in 4Q15. While Valeant previously marketed its dermatology drugs through specialty pharmacies, the company now distributes its products through Walgreens. To learn about the company’s current distribution model, please refer to How Valeant Plans […]
How the Depreciating Euro Has Affected Ferrari’s Profitability
Since its first day of trading on October 21 on the NYSE (New York Stock Exchange), Ferrari (RACE) has fallen by ~10% to $46.62.
Why did Maverick Capital start new position in Autodesk?
Maverick Capital is a $9 billion long-short equity hedge-fund firm, founded in 1990 by Lee S. Ainslie and Sam Wyly. In 2005, Maverick launched a long-only fund and two market-neutral funds with longer than usual investment lockups. The firm is headquartered in Dallas and has an additional office in New York. The fund bought new […]
Valuation: Priceline Versus Its Peers
As of November 6, 2015, Priceline’s forward PE ratio stood at 21.8x, and its average valuation stands at 20x.
How Did Bausch + Lomb’s Top Products Perform in 3Q17?
In 3Q17, Valeant Pharmaceuticals’ Bausch + Lomb’s Soflens generated revenues of $83 million, which was ~5% higher on a YoY basis and ~9% higher QoQ.
Valeant Pharmaceuticals’ Xifaxan and Apriso
In 1H17, Valeant Pharmaceuticals’ (VRX) Xifaxan reported revenues of $418.0 million compared to $408.0 million in 1H16.
Behind Valeant’s Significant Drop in Jublia Sales
In 4Q15, Jublia added $68 million to the top line of Valeant—the sixth-largest revenue contributor in 4Q15, down from the second-largest in 3Q15.
